8 patents currently held
98 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
11 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Of the 98 now held by other companies, 80 name Ionis Pharmaceuticals Inc. as their current owner, and 18 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Jan 2027
Next term end
7
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2027 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends no later than Jun 2030 · Medium confidence
Compositions and Their Uses Directed to Huntingtin
US 7,951,934
The most cited patent in this portfolio, cited by 116 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2027.
Compositions and Methods for Modulation of SMN2 Splicing in a Subject
US 9,926,559
Cited by 71 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Compositions and Methods for Modulation of SMN2 Splicing in a Subject
US 9,717,750
Cited by 26 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends Mar 2028 · High confidence
Cited by 346 later US patents, top 1% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by Ionis Pharmaceuticals, Inc.
Also notable
Ends Apr 2028 · Low confidence
Cited by 119 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
now held by Ionis Pharmaceuticals, Inc.
Also notable
Ends no later than May 2034 · Medium confidence
Cited by 146 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Ionis Pharmaceuticals, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for Modulation of Transthyretin Expression (US 9,061,044) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
What they patent
The 5 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions for Modulating SOD-1 Expression | 2 in force | to Apr 2035 |
| Compositions and Methods for Modulation of SMN2 Splicing in a Subject (2015) | 1 in force | to Jan 2034 |
| Modulation of Signal Transducer and Activator of Transcription 3 (STAT3) Expression | 1 in force | to Jun 2032 |
| Modulation of Transthyretin Expression | 1 in force | to Apr 2031 |
| Compositions and Methods for Modulation of SMN2 Splicing in a Subject (2015) | 1 in force | to Jun 2030 |
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,951,934 | Compositions and Their Uses Directed to Huntingtin held by Ionis Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 8,680,067 | Targeting Micrornas for the Treatment of Liver Cancer held by Regulus Therapeutics Inc. In force · High confidence | In force | High confidence | |
| US 9,717,750 | Compositions and Methods for Modulation of SMN2 Splicing in a Subject In force · Medium confidence | In force | Medium confidence | |
| US 9,061,044 | Modulation of Transthyretin Expression held by Ionis Pharmaceuticals, Inc. In force · Low confidence | In force | Low confidence | |
| US 9,359,608 | Modulation of Signal Transducer and Activator of Transcription 3 (STAT3) Expression In force · High confidence | In force | High confidence | |
| US 9,926,559 | Compositions and Methods for Modulation of SMN2 Splicing in a Subject held by Biogen Ma Inc. In force · High confidence | In force | High confidence | |
| US 10,669,546 | Compositions for Modulating SOD-1 Expression held by Biogen Ma Inc. In force · High confidence | In force | High confidence | |
| US 10,968,453 | Compositions for Modulating SOD-1 Expression held by Biogen Ma Inc. In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 98 patents in force now held by others · 280 patents ended · 3 applications pending · 677 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.